Stockholm, Sweden  Press release November 6, 2019

Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019

STOCKHOLM — November 6, 2019 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from the clinical program evaluating its lead candidate melflufen in multiple myeloma and Light Chain (AL) Amyloidosis have been selected for six poster presentations to be featured at the American Society of Hematology (ASH) 2019 Annual Meeting taking place December 7-10 in Orlando, Florida. Melflufen is a peptide-conjugated alkylator belonging to the novel class of Peptidase Enhanced Cytotoxics (PEnC).

A wide range of clinical and preclinical data for melflufen in both multiple myeloma and AL amyloidosis will be presented at the ASH annual meeting. Two key data sets that will be presented are;

- Updated efficacy and safety data from pivotal phase 2 HORIZON trial evaluating melflufen in patients with relapsed/refractory multiple myeloma (RRMM). The data will support the New Drug Application filing with U.S. FDA late in the first quarter of 2020.
- First presentation of Progression-Free Survival (PFS) data from the ANCHOR phase 2 combination trial in RRMM patients.

“The acceptance of six abstracts from our robust clinical development program evaluating melflufen in multiple myeloma and AL amyloidosis is a significant validation of Oncopeptides’ progress in advancing our pipeline and conducting thorough scientific exploration of the compound. Of particular interest will be long-term follow up data from the HORIZON Phase 2 pivotal trial which is evaluating melflufen in RRMM. These data will form the basis of our New Drug Application for submission to the FDA late in the first quarter of 2020. The update on ANCHOR data will be of high importance as this will be the first time that we present progression free survival (PFS) data with longer term follow up from the combination study,” said Jakob Lindberg, CEO of Oncopeptides. “This ASH Annual Meeting also represents the first time in which we will be presenting data from our early-stage development of melflufen in the treatment of AL Amyloidosis, which is an area of significant unmet need as there are currently no approved therapies available to patients.”

The full ASH Annual Meeting 2019 abstract book can be found at https://www.hematology.org/Annual-Meeting/Abstracts/

The six abstracts detailing melflufen clinical program data and updates that have been accepted for poster presentations at this year’s ASH Annual Meeting and can be found at www.oncopeptides/investor&media/presentations/ASH_Abstracts_2019

Data included in the abstracts currently available on the ASH Annual Meeting website is based on data cut-off dates in second quarter 2019. The final conference presentations will include additional data collected between the abstract submission cutoff and the presentation itself.
Details about the upcoming poster presentations.

**Title:** Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab  
**Presenter:** Maria-Victoria Mateos, Hospital Clinico Universitario de Salamanca, Salamanca, Spain  
**Session:** 653. Myeloma: Therapy, excluding Transplantation: Poster I  
**Date/Time:** Saturday, December 7 at 5:30 – 7:30 p.m.  
**Location:** Hall B

**Title:** Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1  
**Presenter:** Sara Brighen, MD, Division of Hematology University of Torino, Torino, Italy  
**Session:** 653. Myeloma: Therapy, excluding Transplantation: Poster I  
**Date/Time:** Saturday, December 7 at 5:30 – 7:30 p.m.  
**Location:** Hall B

**Title:** OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis  
**Presenter:** Stefan Schönland, MD, Medizinische Klinik V and Amyloidosis Center, Universitätsklinikum Heidelberg, Heidelberg, Germany  
**Session:** 653. Myeloma: Therapy, excluding Transplantation: Poster II  
**Date/Time:** Sunday, December 8 at 6:00 – 8:00 p.m.  
**Location:** Hall B

**Title:** ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI)  
**Presenter:** Enrique M. Ocio, MD, University Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain  
**Session:** 653. Myeloma: Therapy, excluding Transplantation: Poster II  
**Date/Time:** Sunday, December 8 at 6:00 – 8:00 p.m.  
**Location:** Hall B

**Title:** In Vitro and in Vivo Activity of Melflufen in Amyloidosis  
**Presenter:** Kenneth Flanagan, PhD, Oncopeptides AB, Stockholm, Sweden  
**Session:** 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II  
**Date/Time:** Sunday, December 8 at 6:00 – 8:00 p.m.  
**Location:** Hall B

**Title:** The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone  
**Presenter:** Paul G. Richardson, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA  
**Session:** 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Poster II  
**Date/Time:** Sunday, December 8 at 6:00 – 8:00 p.m.  
**Location:** Hall B
For more information, please contact:
Jakob Lindberg, CEO of Oncopetides
E-mail: jakob.lindberg@oncopetides.com
Telephone: +46 615 20 40

Rein Piir, Head of Investor Relations at Oncopetides
E-mail: rein.piir@oncopetides.com
Cell phone: +46 70 853 72 92

This information was submitted for publication at 15.00 CET on November 6, 2019.

About melfluken
Melfufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. Melfufen is rapidly taken up by myeloma cells due to its high lipophilicity and immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. In vitro, melfufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the peptidase cleavage, and induces irreversible DNA damage and apoptosis. Melfufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.

About Oncopetides
Oncopetides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melfufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melfufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment. Oncopetides’ headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

More information is available on www.oncopetides.com.